

Cerebrolysin in DG NR Guideline

Cerebrolysin is included in the evidence-based S3-Guideline of the German Society for Neurorehabilitation

- Cerebrolysin is the best ranked medication DG NR Guidelines
- Confirmation of CARS treatment concept
- Cerebrolysin in 2 new European guidelines within two years

Cerebrolysin[®]

Reconnecting Neurons.
Empowering for Life.


Cerebrolysin® inclusions in 2 EU Guidelines within 2 Years!

S3 guideline "Rehabilitative therapy for arm paresis following a stroke"

→ Arm paresis is one of the most common damages resulting from brain damage, such as a stroke!

“Cerebrolysin

... the drug should be started as quickly as possible (from 24 to 72 hours after the stroke) and, if tolerated, prescribed for **21 days**, once a day, intravenously, in addition to rehabilitation (**evidence 1b**, assessment of effects: moderate quality; **recommendation grade B**; strong consensus)."



- Cerebrolysin is the **best assessed medication** in the guideline
- **CARS treatment concept confirmed!**
- Recovery of arm function has a **significant impact on quality of life (QoL) and activities of daily living (ADL)**



full guideline
(German)

Titel	S3 guideline "Rehabilitative therapy for arm paresis following a stroke" of DGNR*
Author	Prof. Dr. med. Thomas Platz; Medical Director Research, BDH (Bundesverband Rehabilitation) Federal Rehabilitation Association, Head of Neurorehabilitation Working Group, Greifswald University Medicine.
Quality	The quality of the evidence was assessed according to GRADE!

*DGNR: German Society for Neuro-Rehabilitation

ABBREVIATED PRESCRIBING INFORMATION. Name of the medicinal product: Cerebrolysin - Solution for injection. Qualitative and quantitative composition: One ml contains 215.2 mg of Cerebrolysin concentrate in aqueous solution. List of excipients: Sodium hydroxide and water for injection. Therapeutic indications: For treatment of cerebrovascular disorders. Especially in the following indications: Senile dementia of Alzheimer's type. Vascular dementia. Stroke. Craniocerebral trauma (commotio and contusio). Contraindications: Hypersensitivity to one of the components of the drug, epilepsy, severe renal impairment. Marketing Authorisation Holder: EVER Neuro Pharma GmbH, A-4866 Unterach. Only available on prescription and in pharmacies. More information about pharmaceutical form, posology and method of administration, special warnings and precautions for use, interaction with other medicinal products and other forms of interaction, fertility, pregnancy and lactation, effects on ability to drive and use machines, undesirable effects, overdose, pharmacodynamics properties, pharmacokinetic properties, pre-clinical safety data, incompatibilities, shelf life, special precautions for storage, nature and contents of the container and special precautions for disposal is available in the summary of product characteristics.

Copyright © 2020 by EVER Neuro Pharma GmbH, Oberburgau 3, 4866 Unterach, Austria. All rights reserved. No part of this brochure may be reproduced in any form or by any electronic or mechanical means, including information storage and retrieval systems, without permission in writing from the publisher. Cerebrolysin is a registered trademark of EVER Neuro Pharma GmbH, 4866 Unterach, Austria

CERE/INT/08/2020/19